A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
BioNTech SE
Ipsen
Pfizer
Eli Lilly and Company
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
ImmunityBio, Inc.
CStone Pharmaceuticals
Corcept Therapeutics
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
ImmunityBio, Inc.
Bristol-Myers Squibb
Gilead Sciences
Revolution Medicines, Inc.
Lumos Pharma
Eli Lilly and Company
Novartis
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Arcus Biosciences, Inc.
Incyte Corporation
AstraZeneca
Amgen
AstraZeneca
Bristol-Myers Squibb
iOnctura
AstraZeneca
Merck Sharp & Dohme LLC
InxMed (Shanghai) Co., Ltd.
Corcept Therapeutics
Bristol-Myers Squibb
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
EBG MedAustron GmbH
Genelux Corporation
Gilead Sciences
Hoffmann-La Roche
Hoffmann-La Roche
Akeso
Pfizer
Astellas Pharma Inc
Astellas Pharma Inc
Merck Sharp & Dohme LLC